Table 1:
Characteristics of 39 eligible and evaluable patients (by dinutuximab infusion schedule and total)
| 2-day schedule (N=30) | 4 –day schedule (N=9) | All (N=39) | |||||
|---|---|---|---|---|---|---|---|
| Number | Percent | Number | Percent | Number | Percent | ||
| Age at enrollment | |||||||
| <21 years | 25 | 83% | 8 | 89% | 33 | 85% | |
| 21+ | 5 | 17% | 1 | 11% | 6 | 15% | |
| Sex | |||||||
| Male | 18 | 60% | 4 | 44% | 22 | 56% | |
| Female | 12 | 40% | 5 | 56% | 17 | 44% | |
| Race | |||||||
| White | 21 | 70% | 6 | 67% | 27 | 69% | |
| Black | 3 | 10% | 1 | 11% | 4 | 10% | |
| Other | 1 | 3% | 2 | 22% | 3 | 8% | |
| Unknown/not reported | 5 | 17% | 0 | 0% | 5 | 13% | |
| Metastatic disease at initial diagnosis | |||||||
| Yes | 9 | 30% | 1 | 11% | 10 | 26% | |
| No | 21 | 70% | 8 | 89% | 29 | 74% | |
| Number of recurrences prior to enrollment | |||||||
| 1 | 21 | 70% | 7 | 78% | 28 | 72% | |
| 2 | 9 | 30% | 2 | 22% | 11 | 28% | |